Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2019

View Archived Issues

mRNA-based vaccine elicits neoantigen specific T-cell responses in common epithelial cancers

Genentech initiates phase II study of RO-7171009 in geographic atrophy secondary to AMD

Recruitment ongoing in phase I study of NNC0268-0965

Phase Ib/II data presented for ralimetinib in combination with chemotherapy in ovarian cancer

New phase Ib trial studies gevokizumab for metastatic colorectal, gastroesophageal and renal cancers

Phase I study to assess DDO-3055 in healthy volunteers and patients with chronic kidney disease

Celgene initiates phase I study of CC-92252

EDP-938 achieves primary and secondary endpoints in phase IIa human challenge study

Phase III SANET-ep study of surufatinib meets primary endpoint at interim analysis

AMG-510 demonstrates safety and preliminary antitumor activity in KRAS G12C mutant tumors

5F9 shows promising safety and activity both as monotherapy and in combination with azacitidine

Phase I/II data reported for CPX-351 in pediatric patients with relapsed AML

Autolus describes cells comprisnig CARs or or T-cell receptors and a beta2-microglobulin ectodomain

Okayama University patents 89Zr-labeled scFv targeting human mesothelin compositions

Janssen Biotech patents human umbilical cord tissue-derived cells

First phase II data presented for Imago's IMG-7899 in myelofibrosis

EHA 2019: AWOL microbiome cells rile up blood stem cells

CRISPR without DNA breaks

New oncolytic viruses presented by Kagoshima University

Hiroshima University, 3-D Matrix present anticancer microRNAs

Emapalumab proven efficacious in sJIA patients with MAS/HLH

Krystal files IND for first-in-human study of KB-105 for autosomal recessive congenital ichthyosis

TLC reports data from part 1 of phase II bunionectomy trial of TLC-590

Elthera receives funding through E.U.'s Horizon 2020 program

Extracellular vesicles deliver antiaging enzyme

Antibody-antibiotic conjugate DSTA-4637S well tolerated in phase I study

Telaglenastat doubles PFS in heavily pretreated patients with advanced RCC in ENTRATA trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.